Business Context and Reporting Period
This Form 8-K is a current report filed by Klotho Neurosciences, Inc. (not Greenland Mines Ltd) on May 28, 2025. The filing documents the results of a special meeting of stockholders held on the same date. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Omaha, NE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results rather than financial performance.
Material Changes and Voting Results
Stockholders approved a proposal to amend the Company's Second Amended and Restated Certificate of Incorporation to effect a reverse stock split of outstanding common stock. The exchange ratio is set between one-for-2 to one-for-50, to be determined by the Board of Directors.
- Shares Outstanding (Record Date): 28,510,632
- Shares Present (Quorum): 20,321,223
- Votes For: 18,977,235
- Votes Against: 1,343,426
- Abstentions: 562
- Broker Non-Votes: 0
Due to the approval of the reverse stock split, the proposal to adjourn the meeting to solicit additional proxies was deemed moot and was not voted upon.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on future operations, or a discussion of risks and contingencies beyond the execution of the reverse stock split. The primary unusual item is the significant reduction in share count pending the Board's determination of the specific split ratio.
Investor Verification Checklist
- Verify the exact reverse stock split ratio once determined by the Board of Directors (range: 1-for-2 to 1-for-50).
- Confirm the effective date of the reverse stock split and the impact on the trading symbol (KLTO) and warrants (KLTOW).
- Review subsequent filings for any changes to the Company's capitalization table post-split.
- Note the discrepancy between the request metadata ("Greenland Mines Ltd") and the actual registrant ("Klotho Neurosciences, Inc.").